31 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244 Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446 Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts https://www.zacks.com/stock/news/2237621/bristol-myers-squibb-bmy-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2237621 Mar 07, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks? https://www.fool.com/investing/2024/02/17/is-it-too-late-to-buy-these-2-brilliant-passive-in/?source=iedfolrf0000001 Feb 17, 2024 - Patience will be rewarded with these stocks.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414 Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program https://www.zacks.com/stock/news/2223497/jazz-boosts-oncology-pipeline-with-kras-inhibitor-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2223497 Feb 08, 2024 - JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922 Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/02/bristol-myers-squibb-bmy-q4-2023-earnings-call-tra/?source=iedfolrf0000001 Feb 02, 2024 - BMY earnings call for the period ending December 31, 2023.
BLS Jobs Up Big: 353K, 3.7% Unemployment https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-3-7-unemployment?cid=CS-ZC-FT-ahead_of_wall_street-2220369 Feb 02, 2024 - 353K new jobs created for January are nearly double the 180K or so analysts were looking for.

Pages: 1234

Page 1>